Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis

Status Completed

Clinical Trial Summary

Patients with portal vein thrombosis, who have chronic liver diseases especially liver cirrhosis associated with low levels of AT III, will receive intravenous injection of NPB-06 or placebo. The superiority of NPB-06 to placebo as anticoagulative agent will be verified in a randomized, double-blind, parallel-assignment design based on the proportion of patients obtained complete recanalization or partial recanalization of portal vein thrombosis.

The safety of NPB-06 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and 21 days after administration in comparison with the placebo group.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02250391
Study type	Interventional
Source	Nihon Pharmaceutical Co., Ltd
Contact
Status	Completed
Phase	Phase 3
Start date	September 2014
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03631147` - The Effect of Rifaximin on Portal Vein Thrombosis	N/A
Recruiting	`NCT05625893` - Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion	Phase 2
Completed	`NCT05012501` - Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients
Terminated	`NCT00769873` - Anticoagulation Post Laparoscopic Splenectomy	Phase 2
Recruiting	`NCT05123326` - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed	`NCT01095185` - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding	Phase 3
Completed	`NCT02585713` - Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism	Phase 3
Not yet recruiting	`NCT06117488` - Risk Factors and Management Outcome of Chronic Portal Vein Thrombosis in Children
Completed	`NCT01326949` - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis	N/A
Not yet recruiting	`NCT05339581` - IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation	N/A
Recruiting	`NCT03902678` - Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma	N/A
Not yet recruiting	`NCT06319131` - Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT	N/A
Recruiting	`NCT03193502` - Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis	Phase 3
Completed	`NCT03201367` - Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV	N/A
Completed	`NCT03477149` - EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications	N/A
Recruiting	`NCT02398357` - The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis	Phase 4
Completed	`NCT01556282` - TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis	N/A
Withdrawn	`NCT01631877` - Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver	N/A
Recruiting	`NCT04433481` - Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis	N/A
Not yet recruiting	`NCT05872841` - H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis	Phase 2